Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E77.21 EPS (ttm)1.63 Insider Own0.40% Shs Outstand222.52M Perf Week2.47%
Market Cap27.95B Forward P/E22.30 EPS next Y5.63 Insider Trans-7.17% Shs Float215.94M Perf Month4.64%
Income368.10M PEG4.25 EPS next Q1.27 Inst Own96.80% Short Float2.00% Perf Quarter-3.41%
Sales2.95B P/S9.46 EPS this Y-79.50% Inst Trans-1.28% Short Ratio1.98 Perf Half Y-9.13%
Book/sh37.93 P/B3.31 EPS next Y21.51% ROA2.80% Target Price171.67 Perf Year-33.44%
Cash/sh5.90 P/C21.29 EPS next 5Y18.18% ROE4.50% 52W Range110.56 - 193.45 Perf YTD-34.14%
Dividend- P/FCF- EPS past 5Y5.10% ROI1.60% 52W High-35.06% Beta1.41
Dividend %- Quick Ratio2.70 Sales past 5Y36.90% Gross Margin91.60% 52W Low13.62% ATR5.52
Employees2924 Current Ratio3.10 Sales Q/Q19.90% Oper. Margin21.60% RSI (14)54.28 Volatility2.64% 4.31%
OptionableYes Debt/Eq0.38 EPS Q/Q151.70% Profit Margin12.50% Rel Volume1.22 Prev Close124.17
ShortableYes LT Debt/Eq0.37 EarningsOct 27 BMO Payout0.00% Avg Volume2.19M Price125.62
Recom1.90 SMA203.58% SMA502.24% SMA200-5.42% Volume2,646,052 Change1.17%
Nov-03-16Initiated Deutsche Bank Buy $164
Oct-28-16Upgrade Goldman Neutral → Buy
Oct-28-16Upgrade FBR & Co. Underperform → Mkt Perform $92 → $130
Oct-28-16Reiterated Wedbush Neutral $132 → $135
Sep-23-16Initiated Wedbush Neutral $132
Sep-16-16Reiterated FBR & Co. Underperform $82 → $92
Sep-15-16Initiated FBR & Co. Underperform $82
Jul-29-16Reiterated Stifel Buy $195 → $182
Jul-29-16Reiterated Barclays Equal Weight $165 → $150
Jul-13-16Reiterated SunTrust Buy $220 → $197
Jul-13-16Initiated RBC Capital Mkts Outperform $188
Jul-11-16Upgrade Credit Suisse Neutral → Outperform $186 → $165
Jun-27-16Upgrade Citigroup Neutral → Buy
May-09-16Reiterated Barclays Equal Weight $175 → $180
Mar-08-16Downgrade Robert W. Baird Outperform → Neutral $221 → $170
Feb-25-16Initiated Citigroup Buy $165
Feb-04-16Reiterated UBS Buy $222 → $200
Feb-04-16Reiterated Barclays Equal Weight $202 → $175
Jan-20-16Initiated Credit Suisse Neutral
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $225
Dec-07-16 03:58PM  Why Stocks Move When Execs Cancel Presentation Appearances
03:11PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
01:33PM  The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Alexion Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm Business Wire
11:20AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 - ALXN Accesswire
Dec-06-16 03:25PM  SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm Accesswire
11:47AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) & Lead Plaintiff Deadline - January 17, 2017 Accesswire
11:21AM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:07AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017 Accesswire
Dec-05-16 04:35PM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm Accesswire
12:32PM  INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) & Lead Plaintiff Deadline - January 17, 2017 Accesswire
09:05AM  Alexion Presents Data from Ultra-Rare Blood Disorder Study
Dec-04-16 12:00PM  New Data from ALXN1210 Dose-Escalation Study Presented at ASH Show Rapid and Sustained Reductions in LDH in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Business Wire
Dec-02-16 09:48PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
08:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alexion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline ALXN GlobeNewswire
Dec-01-16 03:11PM  SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm Accesswire
02:03PM  Is Alexion Pharmaceuticals, Inc. (ALXN) a Good Stock To Buy? at Insider Monkey
11:45AM  Lifshitz & Miller Law Firm Announces Investigation of Alexion Pharmaceuticals, Inc., Blue Nile, Inc., Hill International, Inc., InfuSystem Holdings Inc., Rent-A-Center, Inc., Treehouse Foods, Inc. and Viking Investments Group, Inc. PR Newswire
10:46AM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : December 1, 2016
Nov-30-16 03:40PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
12:12PM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 -- ALXN Marketwired
07:13AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US : November 30, 2016
12:10AM  U.S. Stocks Edge Higher, Led by Health-Care Gains at The Wall Street Journal
Nov-29-16 05:19PM  Why Thor Industries, Alexion Pharmaceuticals, and Berry Plastics Jumped Today at Motley Fool +5.20%
04:15PM  The Hot Stock: Alexion Pharmaceuticals Jumps 5.2% at Barrons.com
12:31PM  Healthcare Stocks Help Nasdaq Reach New Heights
11:31AM  Stocks Subdued by Lower Commodities Prices at The Wall Street Journal
10:57AM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm Accesswire
10:04AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017 Accesswire
10:00AM  Alexion to Present at the Citi 2016 Global Healthcare Conference Business Wire
09:45AM  Lawsuit for Investors in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares announced by Shareholders Foundation GlobeNewswire
08:16AM  Analysts' Actions -- Goldman Sachs, Johnson & Johnson, Pfizer and More
Nov-28-16 01:58PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Nov-27-16 06:00AM  SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadlin GlobeNewswire
Nov-26-16 09:34PM  Should You Buy General Growth Properties Inc (GGP)? at Insider Monkey
Nov-25-16 08:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alexion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALXN PR Newswire
01:00PM  SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm Accesswire
10:15AM  ALXN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Alexion Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017 GlobeNewswire
Nov-24-16 10:03AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017 Accesswire
Nov-23-16 08:28AM  3 Beaten-Down Biotech Stocks You Can Buy Right Now at Motley Fool
Nov-22-16 06:55PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
03:59PM  Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders According to a Recently Filed Class Action Business Wire
12:24PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm Accesswire
11:33AM  Lockridge Grindal Nauen P.L.L.P. Announces Filing of a Securities Class Action Against Alexion Pharmaceuticals, Inc. GlobeNewswire
08:05AM  SD-809 Could Be a Strong Growth Driver for Teva Pharmaceutical
Nov-21-16 02:20PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
01:23PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 ALXN GlobeNewswire
11:23AM  SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017 GlobeNewswire
09:16AM  BMO Sets Outperform Rating, $26 Target On Ra Pharmaceuticals
Nov-18-16 09:25PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm Business Wire
08:00PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Alexion Pharmaceuticals, Inc. (ALXN) GlobeNewswire
05:25PM  Final Trade: JBLU, CME & more
11:35AM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:24AM  Gilead Sciences: Buy 'Regeneron Lite'Or Just Buy Regeneron? at Barrons.com
10:20AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017 PR Newswire
Nov-17-16 09:32PM  INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
08:00PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Alexion Pharmaceuticals, Inc. To Contact The Firm Before Lead Plaintiff Deadline GlobeNewswire
06:49PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm Business Wire
06:04PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. ALXN Business Wire
05:32PM  New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating Soliris® (eculizumab) Treatment Prior to Transplant Compared to Initiating Treatment Post-Transplant Business Wire
04:13PM  Pomerantz Law Firm Announces the Filing of a Class Action against Alexion Pharmaceuticals, Inc. and Certain Officers ALXN GlobeNewswire
09:28AM  10 biotech companies ripe for a buyout, courtesy of Donald Trump at MarketWatch
Nov-16-16 05:11PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
05:00PM  Alexion Receives NASDAQ Notification Related to the Late Filing of Form 10-Q Business Wire
04:55PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Accesswire
02:30PM  ALEXION NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Alexion Pharmaceuticals, Inc. To Contact The Firm PR Newswire
Nov-15-16 04:23PM  Alexion's Valuation Could Be Getting Pummeled Unnecessarily
02:29PM  Shkreli's Very Bullish Call On Alexion Following Recent Downside: 'Double From Here'
Nov-14-16 01:21PM  Incyte Corporation (INCY), Seattle Genetics, Inc. (SGEN) & Two More: Top Healthcare Hedge Fund Loves These Stocks at Insider Monkey
08:35AM  Alexion (ALXN) Offers Long-Term Phase III Data on Kanuma
12:52AM  [$$] Biotech Company Bloodied by Sales Investigation at The Wall Street Journal
Nov-11-16 04:56PM  The Biggest Loser: Alexion Pharmaceuticals Tumbles 10% at Barrons.com -10.45%
01:10PM  EQUITY ALERT: Khang & Khang LLP Announces an Investigation of Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
12:09PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Pharmaceuticals, Inc. - ALXN PR Newswire
11:25AM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
10:07AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN) Accesswire
09:35AM  Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep at 24/7 Wall St.
08:00AM  New Long-Term Data Presented at AASLD Show Reduction in Liver Fibrosis and Cirrhosis in a Cohort of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (sebelipase alfa) Business Wire
06:47AM  Alexion faces a downside position
Nov-10-16 07:47PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
05:39PM  Bragar Eagel & Squire, P.C. Is Investigating Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire
03:35PM  JPMorgan Believes Its Positive Long-Term Thesis On Alexion Remains Intact
03:23PM  INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
03:14PM  Harwood Feffer LLP Announces Investigation of Alexion Pharmaceuticals, Inc. PR Newswire
02:08PM  Despite Alexion's Internal Investigation, Goldman Standing Behind Its Buy Rating
12:56PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN) PR Newswire
11:38AM  [$$] Biotech Company Bloodied by Sales Investigation at The Wall Street Journal
11:04AM  Alexion Management On Internal Investigation: So Far, So Good
11:03AM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
09:43AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Alexion Pharmaceuticals, Inc.-- ALXN Business Wire
07:57AM  Early movers: KSS, MET, COP, PRTY, BBY, CAS, SHAK, TWTR, MYL & more at CNBC
Nov-09-16 09:01PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire +6.54%
06:49PM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Alexion Pharmaceuticals, Inc. Investors Business Wire
05:49PM  After-hours buzz: TWTR, TASR, SHAK & more at CNBC
05:41PM  [$$] Alexion Pharmaceuticals Investigating Drug's Sales Practices at The Wall Street Journal
04:58PM  Alexion Investigating Allegations About Its Sales Practices
04:56PM  Alexion says investigating Soliris sales practices Reuters
04:56PM  Alexion Pharma shares halted, company to delay quarterly results at MarketWatch
04:47PM  Alexion Drug Sale Practices Target of Internal Investigation
04:38PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wagner Heidi LSVP, Global Government AffairsNov 14Sale115.10596,79131,936Nov 16 06:00 PM
BELL LEONARDDirectorNov 04Option Exercise22.9036,649839,262440,936Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale142.4066895,123404,287Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale140.3436,6495,143,377404,287Nov 07 07:44 PM
BELL LEONARDDirectorOct 31Option Exercise22.901,30029,770406,589Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.3733445,214404,955Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.281,300175,864405,289Nov 02 07:22 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 14Sale120.284,584551,36432,741Oct 18 06:29 PM
Wagner Heidi LSVP, Global Government AffairsOct 03Sale122.4112014,68931,995Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 03Sale122.41293,55037,325Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 13Sale129.003,000387,00037,354Sep 14 04:34 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 12Sale124.2022527,94540,354Sep 14 04:34 PM
Miller EdwardSVP, Chief Compliance OfficerSep 09Sale128.3236747,09316,519Sep 09 06:23 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 06Sale125.941,000125,94040,579Sep 08 04:33 PM
O'Neill JulieEVP. Global OperationsSep 02Sale126.2965082,08935,384Sep 02 05:11 PM
Carmichael ClareEVP, Chief HR OfficerAug 30Sale127.761,000127,76038,577Sep 01 04:57 PM
PARVEN ALVIN SDirectorAug 22Option Exercise18.0115,000270,15021,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 22Sale136.5315,0002,047,9506,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 15Sale135.5170094,8576,373Aug 24 05:33 PM
Carmichael ClareEVP, Chief HR OfficerAug 08Sale137.1416522,62839,577Aug 10 06:23 PM
Moriarty John BEVP & General CounselAug 08Sale137.1413518,51451,225Aug 10 06:23 PM
Sinha VikasEVP & CFOAug 08Sale137.1427737,988178,463Aug 10 06:23 PM
Wagner Heidi LSVP, Global Government AffairsAug 08Sale137.1422230,44532,115Aug 10 06:24 PM
BELL LEONARDDirectorAug 08Sale137.141,010138,511405,289Aug 10 06:22 PM
Hallal DavidCEOAug 08Sale137.1433245,530189,266Aug 10 06:22 PM
Moriarty John BEVP & General CounselJun 13Sale135.72918124,59151,360Jun 14 04:50 PM
MACKAY MARTINEVP & Global Head of R&DMay 16Sale139.204,097570,28442,688May 18 04:36 PM
Wagner Heidi LSVP, Global Government AffairsMay 13Sale138.65537,34832,337May 13 05:48 PM
O'Neill JulieEVP. Global OperationsMar 02Sale149.5565197,35736,034Mar 04 06:21 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 29Sale138.9132945,70116,886Mar 01 06:33 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 29Sale138.91547,50141,579Mar 01 06:34 PM
BELL LEONARDDirectorFeb 29Sale138.923,995554,987742,197Mar 01 06:32 PM
Carmichael ClareEVP, Chief HR OfficerFeb 29Sale138.911,312182,25039,742Mar 01 06:32 PM
Moriarty John BEVP & General CounselFeb 29Sale138.911,201166,83352,278Mar 01 06:32 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 29Sale138.91905125,71443,799Mar 01 06:33 PM
Wagner Heidi LSVP, Global Government AffairsFeb 29Sale138.9154775,98432,390Mar 01 06:34 PM
Hallal DavidCEOFeb 29Sale138.932,014279,800191,012Mar 01 06:32 PM
Sinha VikasEVP & CFOFeb 29Sale138.911,122155,862178,740Mar 01 06:33 PM
MACKAY MARTINEVP & Global Head of R&DFeb 29Sale138.911,000138,91046,785Mar 01 06:34 PM
O'Neill JulieEVP. Global OperationsFeb 29Sale138.9166392,09736,685Mar 01 06:33 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 16Sale143.4918726,83336,633Feb 18 06:29 PM
Hallal DavidCEOFeb 08Sale138.053,946544,763173,026Feb 08 07:57 PM
Moriarty John BEVP & General CounselFeb 08Sale138.082,633363,57748,501Feb 08 07:58 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 08Sale138.071,474203,51844,704Feb 08 07:56 PM
BELL LEONARDDirectorFeb 08Sale138.0911,4741,584,442746,192Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 08Sale138.052,665367,91134,054Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 08Sale138.07942130,06629,937Feb 08 07:57 PM
O'Neill JulieEVP. Global OperationsFeb 08Sale138.07778107,41930,348Feb 08 07:55 PM
MACKAY MARTINEVP & Global Head of R&DFeb 08Sale138.091,966271,48140,785Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 08Sale137.613,890535,316171,862Feb 08 07:56 PM
Hallal DavidCEOFeb 05Sale141.636,722952,043176,972Feb 08 07:57 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 05Sale143.021,051150,31414,215Feb 08 07:57 PM
Moriarty John BEVP & General CounselFeb 05Sale143.451,969282,44751,134Feb 08 07:58 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 05Sale143.481,970282,66146,178Feb 08 07:56 PM
BELL LEONARDDirectorFeb 05Sale143.122,136305,702757,666Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 05Sale141.761,993282,53836,719Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 05Sale143.14997142,70830,879Feb 08 07:57 PM
O'Neill JulieEVP. Global OperationsFeb 05Sale143.232,080297,91931,126Feb 08 07:55 PM
MACKAY MARTINEVP & Global Head of R&DFeb 05Sale141.562,005283,82342,751Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 05Sale143.501,954280,404175,752Feb 08 07:56 PM
Hallal DavidCEOFeb 04Sale143.8362990,469142,558Feb 08 07:57 PM
BELL LEONARDDirectorFeb 04Sale143.832,262325,338746,997Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 04Sale143.8420729,77426,949Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 04Sale143.8416924,30925,747Feb 08 07:57 PM
Sinha VikasEVP & CFOFeb 04Sale143.83703101,116165,943Feb 08 07:56 PM
BELL LEONARDDirectorDec 29Option Exercise22.9028,968663,367778,227Dec 29 05:03 PM
BELL LEONARDDirectorDec 29Sale190.8028,9685,526,983749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 28Option Exercise22.904009,160749,659Dec 29 05:03 PM
BELL LEONARDDirectorDec 28Sale190.1540076,060749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 24Option Exercise22.905,632128,973754,891Dec 29 05:03 PM
BELL LEONARDDirectorDec 24Sale190.005,6321,070,080749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 17Option Exercise22.9070,0001,603,000819,259Dec 21 05:43 PM
BELL LEONARDDirectorDec 17Sale187.6970,00013,137,985749,259Dec 21 05:43 PM
NORBY R DOUGLASDirectorDec 11Sale187.7145,4428,530,12432,481Dec 15 05:36 PM
Moriarty John BEVP & General CounselDec 11Sale182.73943172,31141,340Dec 15 05:35 PM
Veneman Ann MDirectorDec 11Sale187.48895167,7953,252Dec 15 05:36 PM
BELL LEONARDDirectorDec 11Sale187.5621,3193,998,527727,940Dec 15 05:36 PM